

## Registration Fees

The registration fee for Delegates and Presenters includes:

- attendance to all scientific sessions (limited to seats availability)
- entrance to the exhibition area
- certificate of attendance
- badge and congress kit
- coffee break and lunch according to the programme
- 22% Italian VAT (tax)

	EARLY BIRD FEE From July 1 <sup>st</sup> to October 31 <sup>st</sup> 2017	REGULAR FEE From November 1 <sup>st</sup> 2017 to February 28 <sup>th</sup> 2018	LATE FEE from March 1 <sup>st</sup> and ONSITE
Medical Doctor/ Biologist	€ 400,00	€ 500,00	€ 600,00
Resident, Nurses and Midwives	€ 150,00	€ 180,00	€ 230,00
Low and Middle Income Countries*	€ 300,00	€ 350,00	€ 450,00

\*LMICs: Afghanistan, Angola, Armenia, Azerbaijan, Bangladesh, Belize, Benin, Bhutan, Burkina Faso, Burundi, Cambodia, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Dem. Rep. Cote d'Ivoire, Cuba, Dominican Republic, El Salvador, Equatorial Guinea, Eritrea, Ethiopia, Fiji, Gambia, Ghana, Guatemala, Guinea, Guinea-Bissau, Haiti, Honduras, India, Jamaica, Kazakhstan, Kenya, Kiribati, Kyrgyz Republic, Laos, Lesotho, Liberia, Madagascar, Malawi, Maldives, Mali, Marshall Islands, Mauritania, Micronesia, Fed. Sts., Moldova, Mongolia, Mozambique, Myanmar, Namibia, Nepal, Nicaragua, Niger, Nigeria, Pakistan, Papua New Guinea, Rwanda, Samoa, Sao Tome and Principe, Senegal, Sierra Leone, Solomon Islands, Somalia, South Africa, Sri Lanka, St. Vincent and the Grenadines, Sudan, Suriname, Swaziland, Tajikistan, Tanzania, Timor-Leste, Togo, Tonga, Turkmenistan, Uganda, Uzbekistan, Vanuatu, Vietnam, Yemen, Zambia, Zimbabwe

Patronage:



Organizing Secretariat:



Adria Congrex srl  
Via Sassonia, 30 - 47922 Rimini  
Tel. 0541.305873 - Fax 0541.305842  
c.imola@adriacongrex.it

[www.hpvrome.com](http://www.hpvrome.com)

# ROME, APRIL 12-13 2018

## COURSE DIRECTORS

Antonio Frega, Cesare Gentili and Philip Davies



## XIII INTERNATIONAL WORKSHOP ON LOWER GENITAL TRACT PATHOLOGY

### HPV Diseases and Cervical Cancer: Summing Up

## Thursday 12 April 2018

### Morning

#### ROOM A (Plenary session)

##### 8.30-10.20 HPV Infection and Carcinogenesis

- HPV Infection and Carcinogenesis: a public health perspective.
- Human papillomavirus infection and the induction of neoplasia.
- The natural history of HPV infection in screening age women; do we have enough data to really understand what is happening in this age group?
- Persistent vs repeated infections; can we tell the difference and does it make a difference to cervical carcinogenesis?
- HPV infection in men; do we understand the natural history and clinical implications for men and their partners?

##### 10.20-11.00 Epidemiology of Cervical Cancer and HPV Infection

- Cervical cancer trends around the world; are we making a difference?
- HPV vaccination and its impact on HPV infection rates around the world.

##### 11.30-13.00 Cervical Screening

- The current status of cervical screening programmes around the world; are we making progress where it is needed most or just further improving the best?
- HPV testing for primary screening; who is doing what?
- The latest data from the HPV primary screening programmes; the benefits and the challenges that remain to be solved.
- Cervical screening; is there still a role for the Pap test?

#### ROOM B

##### 9.00-13.00 Free Communications

### Afternoon

#### ROOM A

##### 14.30-15.40 Cervical Screening: the New Challenges

- Estimating the impact of HPV primary screening and HPV vaccination on cervical cancer rates.
- HPV screen positive; what are the triage options and their associated risks.
- Reaching under- or never-screened women; is self-sampling the answer?

##### 15.40-16.50 HPV Positive, What Next?

- HPV screen positive follow-up; what do we see at colposcopy?
- Persistent HPV infection without colposcopically visible cervical disease: how common and what is the appropriate follow-up?
- How does HPV status affect the treatment of low-grade cervical disease?

##### 17.05-18.00 Colposcopy in the Era of HPV Vaccination and HPV Screening

- The implications of HPV vaccination for the practice of colposcopy.
- HPV primary screening; will this affect the accuracy of colposcopy?
- Should colposcopists be re-trained to deal with the realities of the HPV era?

##### 18.00-18.45 Noncompliance with Colposcopy Referral

- Noncompliance with colposcopy referral; the extent of the problem in different countries.
- Why do women decide not to go to colposcopy?
- Methods to minimize default from colposcopy; what works and what does not.

#### ROOM B

##### 14.30-16.50 Updates in Molecular Biology and Cytopathology

- Latent papillomavirus infections: the role of HPV test.
- Getting around in molecular testing jungle: what clinicians and pathologists should know to properly interpret the results
- Investigating diagnostic problems of CIN1 and CIN2 associated with high-risk HPV by combining the novel molecular biomarker PanHPVE4 with P16INK4a.
- The role of the cytology and human papillomavirus genotyping in screening for anal cancer
- Morphologic signs of HPV infection and integration.
- Is the new Bethesda system tailored for the HVP screening and molecular diagnosis?
- The triage cytology: what molecular biology cannot provide.

##### 17.10-18.30 Opening Forum

## Friday 13 April 2018

### Morning

#### ROOM A (Plenary session)

##### 8.30-10.30 HPV Vaccination

- HPV vaccination around the world today: the programs and the coverage rates.
- HPV vaccination; long-term efficacy and protection. What are the data?
- Screening in vaccinated and unvaccinated women: are two algorithms necessary and if so how do we implement them?
- HPV vaccination of boys; who is doing what?
- Improving HPV vaccination coverage; what works and what does not.
- The nonavalent HPV vaccine: what changes?

##### 11.10-13.00 Ensuring the Safety and Effectiveness of Colposcopy

- Adverse sequela after the treatment of CIN: an international comparison.
- How can we personalize management of cervical screening positive pregnant women to minimize pregnancy associated morbidity?
- Colposcopy training; the similarities and differences across Europe.
- Quality assurance of colposcopy; the European perspective.
- Quality assurance of colposcopy; the American perspective.

#### ROOM B

##### 8.30-13.00 Free Communications

### Afternoon

#### ROOM A

##### 14.15-15.25 Public Education and Coverage Rates

- Social and psychological impact of HPV testing in cervical screening.
- Reaching under- or never-screened women; is self-sampling the answer?
- The impact of HPV vaccination on cervical cancer screening coverage; are the predictions proving to be true?
- HPV vaccination for adolescents, Pap screening for under-30s, HPV screening for over 30's; how can we effectively communicate all this to ensure high programme participation?

##### 15.25-16.15 HPV and Vaginal Infection

- The role of vaginal microbiome in HPV infection and disease.
- Chlamydia trachomatis infection: implications for HPV status and cervical cancer.
- The effect of intrauterine devices on acquisition and clearance of human papillomavirus.

##### 16.15-17.15 Miscellany

- 16.15 HPV and fertility.
- 16.30 The role of oral contraception and hormone replacement therapy in HPV infection and disease.

#### ROOM B

##### 14.15-17.15 Cervical cytopathology in HPV testing era: interactive slide seminar of cervical cytopathology.

#### ROOM A ( Plenary session)

##### 16.55 Closing Lecture

- HPV infection and disease a bundle of answered questions.

##### 17.15 Presentation of the best 5 free communications and award for the best.

##### 18.00 ECM test

##### 18.20 Awarding of the three best speakers and conclusions

#### SCIENTIFIC COMMITTEE

A. Ciavattini  
R. De Vincenzo  
J. Dillner  
A. Lukic  
B. Moscicki  
K.U. Petry  
W. Prendiville